Trimazosin hydrochloride

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 526505

CAS#: 53746-46-6

Description: Trimazosin hydrochloride is used in the treatment of hypertensive patients failing to respond to thiazides.

Chemical Structure

img
Trimazosin hydrochloride
CAS# 53746-46-6
Instruction

Theoretical Analysis

MedKoo Cat#: 526505
Name: Trimazosin hydrochloride
CAS#: 53746-46-6
Chemical Formula: C20H32ClN5O7
Exact Mass: 489.20
Molecular Weight: 489.954
Elemental Analysis: C, 49.03; H, 6.58; Cl, 7.24; N, 14.29; O, 22.86

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 35795-17-6 (HCl)   53746-46-6 (HCl hydrate)   35795-16-5 (free base)    

Synonym: CP-19106-1; CP19106-1; CP 19106-1; Trimazosin hydrochloride; Trimazosin HCl.

IUPAC/Chemical Name: 2-hydroxy-2-methylpropyl 4-(4-amino-6,7,8-trimethoxyquinazolin-2-yl)piperazine-1-carboxylate hydrochloride hydrate

InChi Key: WXMXALSEIGHTOR-UHFFFAOYSA-N

InChi Code: InChI=1S/C20H29N5O6.ClH.H2O/c1-20(2,27)11-31-19(26)25-8-6-24(7-9-25)18-22-14-12(17(21)23-18)10-13(28-3)15(29-4)16(14)30-5;;/h10,27H,6-9,11H2,1-5H3,(H2,21,22,23);1H;1H2

SMILES Code: O=C(N1CCN(C2=NC(N)=C3C=C(OC)C(OC)=C(OC)C3=N2)CC1)OCC(C)(O)C.[H]Cl.[H]O[H]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 489.95 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Vincent J, Hamilton CA, Reid JL. The cardiovascular effects of trimazosin and prazosin in the rabbit. Clin Exp Pharmacol Physiol. 1986 Aug;13(8):593-608. PubMed PMID: 2878751.

2: Moyer RR. A double-blind study of trimazosin and methyldopa in hypertensive patients receiving polythiazide. Am Heart J. 1983 Nov;106(5 Pt 2):1250-3. PubMed PMID: 6356853.

3: Constantine JW, Lebel W, Weeks R. The hypotensive effect of trimazosin is not caused solely by alpha 1-adrenoceptor blockade. J Cardiovasc Pharmacol. 1984 Jan-Feb;6(1):142-50. PubMed PMID: 6199597.

4: Singleton W, Taylor CR. Effect of trimazosin on serum lipid profiles in hypertensive patients. Am Heart J. 1983 Nov;106(5 Pt 2):1265-8. PubMed PMID: 6356856.

5: Helgeland A. Double-blind comparison of trimazosin and propranolol in essential hypertension. Am Heart J. 1983 Nov;106(5 Pt 2):1253-8. PubMed PMID: 6356854.

6: Vincent J, Elliott HL, Meredith PA, Reid JL. Trimazosin: relationships between hypotensive effect, vascular responsiveness, and drug and metabolite concentrations. J Cardiovasc Pharmacol. 1985 Sep-Oct;7(5):913-8. PubMed PMID: 2413300.

7: Vincent J, Elliott HL, Meredith PA, Hughes DM, Reid JL. The effect of cimetidine on the pharmacokinetics, pharmacodynamics and alpha 1-adrenoceptor responsiveness of trimazosin in man. Eur J Clin Pharmacol. 1985;29(3):301-6. PubMed PMID: 3000797.

8: Reid JL, Meredith PA, Elliott HL. Pharmacokinetics and pharmacodynamics of trimazosin in man. Am Heart J. 1983 Nov;106(5 Pt 2):1222-8. PubMed PMID: 6637788.

9: Oberman A, Pool PE. Trimazosin for the treatment of hypertensive patients failing to respond to thiazides. Am Heart J. 1983 Nov;106(5 Pt 2):1258-64. PubMed PMID: 6356855.

10: Weber MA, Brewer DD, Drayer JI, Aronow WS, Lipson JL, Ricci BA. A vasodilator that avoids renin stimulation and fluid retention: antihypertensive treatment with trimazosin. Clin Pharmacol Ther. 1982 May;31(5):572-8. PubMed PMID: 7042174.

11: Constantine JW, Lebel W, Weeks R. Effects of trimazosin and prazosin on blood pressure and on pressor responses to phenylephrine in rats. Am Heart J. 1983 Nov;106(5 Pt 2):1216-21. PubMed PMID: 6637787.

12: Chrysant SG. Autonomic, systemic, and renal hemodynamic actions of trimazosin in hypertensive patients. Am Heart J. 1983 Nov;106(5 Pt 2):1243-50. PubMed PMID: 6356852.

13: Webb DJ, Hutcheson MJ, Robertson MP, Murray GD, Lorimer AR, Robertson JI. A comparison of atenolol and long-acting trimazosin in mild to moderate essential hypertension. Scott Med J. 1985 Apr;30(2):106-10. PubMed PMID: 3892676.

14: Byyny RL, Nies AS, LoVerde ME, Mitchell WD. Effect of a sustained-release formulation of trimazosin in mild to moderate hypertension. J Clin Pharmacol. 1987 Feb;27(2):101-5. PubMed PMID: 3680560.

15: Hughes MA, Meredith PA, Elliott HL. The determination of trimazosin and its metabolite CP23445 in whole blood by high performance liquid chromatography using fluorescence detection. J Pharmacol Methods. 1984 Aug;12(1):29-34. PubMed PMID: 6536811.

16: Elliott HL, Vincent J, Hughes DM, Meredith PA, Reid JL. Trimazosin in normotensive subjects. Clin Pharmacol Ther. 1984 Feb;35(2):156-60. PubMed PMID: 6141018.

17: Nelson GI, Hussain M, Forsyth D, Wilson J, Silke B, Taylor SH. Haemodynamic effects of selective alpha 1-blockade (trimazosin) in essential hypertension. J Cardiovasc Pharmacol. 1984 Jan-Feb;6(1):176-81. PubMed PMID: 6199601.

18: Taylor CR, Leader JP, Singleton W, Munster EW, Falkner FC, O'Neil JA. Profile of trimazosin: an effective and safe antihypertensive agent. Am Heart J. 1983 Nov;106(5 Pt 2):1269-81. PubMed PMID: 6227228.

19: Singleton W, Saxton CA, Hernandez J, Prichard BN. Postjunctional selectivity of alpha-blockade with prazosin, trimazosin, and UK-33,274 in man. J Cardiovasc Pharmacol. 1982;4 Suppl 1:S145-51. PubMed PMID: 6175830.

20: Constantine JW, Hess HJ. The cardiovascular effects of trimazosin. Eur J Pharmacol. 1981 Sep 11;74(2-3):227-38. PubMed PMID: 6120084.